Biotech company Telix Pharmaceuticals has received clearance from the Chinese National Medical Products Administration (NMPA) ...
An FDA advisory committee on Wednesday unanimously voted against recommending approval of the PARP inhibitor talazoparib (Talzenna) plus enzalutamide (Xtandi) for all patients with metastatic ...
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Bi opsy of the P rostate A voidance S ...
The decision means Northern Ireland remains the only country in the UK where patients with this stage of prostate cancer are ...
MELBOURNE, Australia and INDIANAPOLIS, Jan. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, ...
GG1 prostate cancer can have heterogeneous outcomes, with some patients having intermediate- or high-risk disease, challenging the notion of GG1 as uniformly low-risk. Removing the cancer label for ...
Talzenna plus Xtandi showed a 14-month survival improvement for HRR gene-mutated metastatic castration-resistant prostate cancer, supported by TALAPRO-2 trial data. Nubeqa approval for metastatic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback